DGAP-News Virpax(R) Pharmaceuticals Inc.: Virpax Pharmaceuticals Announces Newly Issued Patent for Probudur(TM)
DGAP-News: Virpax(R) Pharmaceuticals Inc. / Key word(s): Miscellaneous
Virpax Pharmaceuticals Announces Newly Issued Patent for Probudur(TM)
WEST CHESTER, PA, March 2, 2021 - Virpax(R) Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced that the United States Patent and Trademark Office issued US Patent No. 10842745 entitled, "Composition of matter comprising liposome embedded in a polymerix matrix and methods of using same."
This newly issued patent, which is owned by LipoCure Rx and exclusively licensed to Virpax, has 18 claims and expires in 2029. The patent covers a liposomal composition containing bupivacaine as well as additional claims covering methods for providing analgesia in patients by administration of the liposomal compositions.
"We are extremely pleased with the continued development of the patent portfolio for ProbudurTM, our long-acting anesthetic for postoperative pain management. This newly issued patent further broadens our overall intellectual property portfolio," stated Anthony Mack, Chairman and CEO of Virpax.
About Virpax Pharmaceuticals
Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval using its three patented drug delivery platforms. Epoladerm(TM) is a topical diclofenac metered-dose spray film formulation being developed to manage acute musculoskeletal pain and osteoarthritis. Probudur(TM) is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta(TM) is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop its PES200 product candidate to manage post-traumatic stress disorder (PTSD) and its MMS019 product candidate to inhibit viral replication caused by influenza or SARS-CoV-2. For more information, please visit www.virpaxpharma.com.